-
What does a nitrosamine risk assessment include, and how are acceptable intake (AI) limits set (e.g., CPCA for NDSRIs)?
A nitrosamine risk assessment is a structured, product-specific evaluation of where nitrosamines and NDSRIs may form across API synthesis, excipients, manufacturing conditions, and degradation pathways. The outcome prioritizes targets for confirmatory testing and supports setting impurity limits based on acceptable intake (AI); for many NDSRIs with limited toxicology data, carcinogenic potency categorization (CPCA) can be used to derive AI-based limits and support submission-ready documentation.
-
What is confirmatory testing for nitrosamines/NDSRIs, and when is it needed?
Confirmatory testing is targeted analysis used to verify whether specific nitrosamine impurities (including NDSRIs) are present and to quantify them against AI-based limits. It is commonly performed after risk assessment identifies plausible formation routes, after screening indicates a potential signal, or when regulators expect product-specific evidence that your control strategy is effective.
-
How do you develop and validate methods for nitrosamine/NDSRI testing (LC-MS/MS, GC-MS/MS, HRMS)?
Method development focuses on selectivity, ultra-trace sensitivity, and robust performance in your specific matrix. We typically use LC-MS/MS or GC-MS/MS, and apply HRMS when additional specificity is required; validation (or verification) addresses key parameters such as specificity, LOQ/LOD, linearity, accuracy, precision, and matrix effects to support batch release testing and submission-ready data packages.
-
What causes false positives in nitrosamine testing, and how do you resolve them?
False positives can occur at ultra-trace levels due to matrix interferences, background contamination, consumables, reagents/solvents, or instrument carryover. A structured investigation combines contamination control, sample preparation optimization, and orthogonal confirmation (e.g., alternate transitions/ions, alternate chromatography, or complementary techniques) to distinguish true nitrosamines/NDSRIs from artifacts.
-
What is the analytical method lifecycle and why is lifecycle management important?
The analytical method lifecycle refers to the end-to-end process of developing, validating, and maintaining a laboratory method to ensure it reliably measures what it is intended for. Lifecycle management involves ongoing monitoring, improvement, and control of the method and samples, ensuring continued accuracy and compliance over time. At Milestone Pharma, we integrate lifecycle principles into our method development and validation services to support phase-appropriate regulatory readiness and product quality from preclinical through commercialization.
-
Which parameters should be optimized during analytical method development to ensure validation readiness?
To ensure the method is suitable for validation, critical quality attributes should be optimized, including instrument parameters and sample preparation procedures, while ensuring method sensitivity and specificity. Milestone Pharma adopts a science- and risk-based approach for parameter optimization to ensure robust method performance and compliance with regulatory requirements.
Discuss My Project
Speak with an expert about your upcoming project to see how we can help you.